Zhejiang Ouke Biopharmaceutical

Zhejiang Ouke Biopharmaceutical is a China-based biotechnology company dedicated to the development and industrialization of high-purity recombinant protein therapeutics. The company leverages advanced genetic engineering and large-scale mammalian and yeast cell culture systems to produce biological alternatives to human plasma-derived products, addressing chronic shortages in the blood products market. Its lead program, a recombinant human serum albumin (rHSA), is in Phase 3 clinical trials for the treatment of hypoalbuminemia and conditions related to liver cirrhosis and surgery. Additionally, Ouke is developing a pipeline of recombinant coagulation factors, including Factor VIII, to provide safer treatment options for patients with hemophilia A. Headquartered in Huzhou, the company maintains state-of-the-art R&D and GMP-compliant manufacturing facilities designed to support global commercialization of its protein candidates.